French data on the epidemiology and expert healthcare network for epidermolysis bullosa
Journal of the European Academy of Dermatology and Venereology · 2023
DOI: 10.1111/jdv.18826 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Christine Bodemer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Necker-Enfants Malades Hospital, Reference Centre for genodermatoses (MAGEC-Necker) University Paris Centre, Paris, European Network for Rare Skin Di…. Hauptthemen laut MEDLINE: Epidermolysis Bullosa. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Amryt Pharma.
Abstract (Originalsprache)
Dear Editor, Epidermolysis bullosa (EB) is a heterogeneous group of rare genodermatoses characterized by mucocutaneous fragility resulting in recurrent blisters and ulcers. The clinical spectrum is broad, with potentially severe complications, and significant morbidity and mortality.1 EB is classified into four major types, depending on the skin cleavage plane2: EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB) and Kindler EB (KEB). In the absence of curative treatment, patient management mainly relies on early diagnosis, a multidisciplinary approach, and the use of complex dressings, nutritional support, and medical or surgical interventions.1,3,4 Heterogenous EB prevalence rates have been reported across countries worldwide, with values ranging from 4.0 to 54.0/million population, reflecting variabilities in populations and data sources.5– 7 In France, no epidemiological data have been published, but data on EB patients collected through the network of national and local rare disease centres were available from the French national registry for rare diseases (BNDMR).8 A retrospective analysis has been performed using BNDMR data from EB patients registered between January 2007 and December 2021. Included patients were diagnosed following clinical examination and systematic skin biopsy with immunofluorescence mapping. Genetic analysis was performed in the majority of cases. Data collected included patient age, sex, EB type, vital status, diagnostic assessment and dates and reasons for expert centre visits. EB prevalence was calculated for the whole study population and for each EB type by dividing the number of EB patients alive on Received: 20 July 2022 | Accepted: 14 December 2022
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Necker-Enfants Malades Hospital, Reference Centre for genodermatoses (MAGEC-Necker) University Paris Centre, Paris, European Network for Rare Skin Disorders (ERN-Skin), Paris, France.
- BNDMR - AP-HP - Campus Picpus Département I&D, Paris, France.
- DEBRA France, Marseille, France.
- Centre de Recherche des Cordeliers Paris, Université Paris Cité, HeKA INSERM, INRIA Paris, Paris, France.
ORCID-Profile: Christine Bodemer
Förderung
- Amryt Pharma
Zitieren
APA
Bodemer, C., Soussand, L., Sandrin, A., Khatim, A., Sauvestre, A., Elarouci, N., & Jannot, A. S. (2023). French data on the epidemiology and expert healthcare network for epidermolysis bullosa. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.18826
Vancouver
Bodemer C, Soussand L, Sandrin A, Khatim A, Sauvestre A, Elarouci N, et al. French data on the epidemiology and expert healthcare network for epidermolysis bullosa. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.18826
BibTeX
@article{Bodemer2023,
author = {Bodemer, Christine and Soussand, Louis and Sandrin, Arnaud and Khatim, Ahlem and Sauvestre, Angélique and Elarouci, Nabila and Jannot, Anne-Sophie},
title = {French data on the epidemiology and expert healthcare network for epidermolysis bullosa},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2023},
doi = {10.1111/jdv.18826}
}
EUVIMED